Heron Therapeutics Inc HRTX:NASDAQ

Last Price$13.55NASDAQ Closing Price as of 4:15PM ET 4/07/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.77(6.03%)
Bid (Size)$12.80 (10)
Ask (Size)$13.60 (4)
Day Low / High$12.82 - 13.59
Volume1.5 M

View Biotechnology IndustryPeer Comparison as of 04/07/2020


Heron Therapeutics Inc ( NASDAQ )

Price: $13.55
Change: +0.77 (6.03%)
Volume: 1.5 M
4:15PM ET 4/07/2020

Myriad Genetics Inc ( NASDAQ )

Price: $14.79
Change: -0.53 (3.46%)
Volume: 933.7 K
3:59PM ET 4/07/2020

Cortexyme Inc ( NASDAQ )

Price: $36.24
Change: -2.56 (6.60%)
Volume: 167.9 K
3:59PM ET 4/07/2020

Editas Medicine Inc ( NASDAQ )

Price: $21.12
Change: -0.23 (1.08%)
Volume: 1.4 M
4:00PM ET 4/07/2020

Twist Bioscience Corp ( NASDAQ )

Price: $26.40
Change: -3.33 (11.20%)
Volume: 408.4 K
4:00PM ET 4/07/2020

Read more news Recent News

Heron Therapeutics Slips After Posting Worse-Than-Expected Q4 Loss Per Share; Revenue Tops Consensus
2:28PM ET 3/02/2020 MT Newswires

Heron Therapeutics (HRTX) on Monday posted a Q4 net loss of $0.65 per share, compared with a net loss of $0.63 per share a year earlier and wider than the...

Heron Therapeutics Down 4% After FDA Extends Review Period for HTX-011 Non-Opioid Pain Medication
1:57PM ET 2/20/2020 MT Newswires

Heron Therapeutics (HRTX) dropped 4% after the company said the US Food and Drug Administration extended the review period for the company's HTX-011 drug...

Analyst Actions: Needham & Co Cuts Heron Therapeutics Price Target to $48 From $50, Maintains Buy Rating
11:13AM ET 2/20/2020 MT Newswires

Heron Therapeutics' (HRTX) average rating among analysts is a buy, with an average price target of $47. Price: 20.21, Change: -1.45, Percent Change: -6.69...

Heron Therapeutics Says Drug for Postoperative Pain Receives Priority Review Status From Health Canada
9:11AM ET 12/03/2019 MT Newswires

Heron Therapeutics (HRTX) said Tuesday that Health Canada has accepted and granted a Priority Review Status for HTX-011, which is intended for the...

Company Profile

Business DescriptionHeron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA. View company web site for more details
Address4242 Campus Point Court
San Diego, California 92121
Number of Employees198
Recent SEC Filing03/02/202010-K
President, Chief Executive Officer & DirectorBarry D. Quart
Chief Financial Officer & Senior VP-FinanceRobert E. Hoffman
Chief Scientific Officer & SVP-PharmaceuticalThomas B. Ottoboni
Chief Medical OfficerChris M. Storgard

Company Highlights

Price Open$13.41
Previous Close$12.78
52 Week Range$9.60 - 26.81
Market Capitalization$1.2 B
Shares Outstanding90.4 M
SectorHealth Technology
Next Earnings Announcement05/14/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.51
Beta vs. S&P 500N/A
Revenue$77.5 M
Net Profit Margin-140.27%
Return on Equity-61.74%

Analyst Ratings as of 03/02/2020

Consensus RecommendationConsensus Icon
Powered by Factset